Literature DB >> 21892702

Impact of mammographic screening on the detection of good and poor prognosis breast cancers.

Laura J Esserman1, Yiwey Shieh, Emiel J T Rutgers, Michael Knauer, Valesca P Retèl, Stella Mook, Annuska M Glas, Dan H Moore, Sabine Linn, Flora E van Leeuwen, Laura J van 't Veer.   

Abstract

We sought to compare the molecular signature of node negative cancers from two cohorts 15 years apart, to determine if there is molecular evidence of increase in low and ultralow risk cancers over time. We studied the impact of age, time period of diagnosis, and mammographic screening on biology of tumors where The Netherlands Cancer Institute 70-gene prognosis signature was generated as part of 2 validation series, one retrospective (1984-1992), Cohort 1, and one prospective (2004-2006), Cohort 2. A total of 866 patients were analyzed. Regardless of time period of diagnosis, the proportion of T1, grade 1, hormone receptor positive (HR) tumors, and good prognosis by 70-gene signature significantly increases as age increases (P < 0.01). In women aged 49-60, the time period of diagnosis significantly affects the proportion of cancers that were NKI 70-gene low risk: 40.6% (67/165) compared with 58% (119/205) for Cohorts 1 and 2, respectively. This is in contrast to the absence of a significant change for women under age 40, where 25% (17/68) and 30% (17/56) were low risk in Cohorts 1 and 2, respectively. In women aged 49-60, using an ultralow risk threshold of the 70-gene signature, 10% of tumors in Cohort 1 were ultralow risk compared with 30% for women with screen-detected cancers in Cohort 2. Older age and method of detection (screening) are associated with a higher likelihood of a biologically low risk tumor. In women over age 50, biologically low risk tumors are frequent and tools that classify risk may minimize overtreatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21892702      PMCID: PMC5646368          DOI: 10.1007/s10549-011-1748-z

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  23 in total

Review 1.  Overdiagnosis in cancer.

Authors:  H Gilbert Welch; William C Black
Journal:  J Natl Cancer Inst       Date:  2010-04-22       Impact factor: 13.506

2.  Solving the overdiagnosis dilemma.

Authors:  Laura Esserman; Ian Thompson
Journal:  J Natl Cancer Inst       Date:  2010-04-22       Impact factor: 13.506

3.  Gene expression profiling predicts clinical outcome of breast cancer.

Authors:  Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

4.  Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer.

Authors:  Britta Weigelt; Zhiyuan Hu; Xiaping He; Chad Livasy; Lisa A Carey; Matthew G Ewend; Annuska M Glas; Charles M Perou; Laura J Van't Veer
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

5.  Gene expression profiles of primary breast tumors maintained in distant metastases.

Authors:  Britta Weigelt; Annuska M Glas; Lodewyk F A Wessels; Anke T Witteveen; Johannes L Peterse; Laura J van't Veer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-09       Impact factor: 11.205

6.  Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature.

Authors:  Stella Mook; Michael Knauer; Jolien M Bueno-de-Mesquita; Valesca P Retel; Jelle Wesseling; Sabine C Linn; Laura J Van't Veer; Emiel J Rutgers
Journal:  Ann Surg Oncol       Date:  2010-01-22       Impact factor: 5.344

7.  The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age.

Authors:  S Mook; M K Schmidt; B Weigelt; B Kreike; I Eekhout; M J van de Vijver; A M Glas; A Floore; E J T Rutgers; L J van 't Veer
Journal:  Ann Oncol       Date:  2009-10-13       Impact factor: 32.976

8.  The decrease in breast-cancer incidence in 2003 in the United States.

Authors:  Peter M Ravdin; Kathleen A Cronin; Nadia Howlader; Christine D Berg; Rowan T Chlebowski; Eric J Feuer; Brenda K Edwards; Donald A Berry
Journal:  N Engl J Med       Date:  2007-04-19       Impact factor: 91.245

9.  Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

Authors:  Jolien M Bueno-de-Mesquita; Wim H van Harten; Valesca P Retel; Laura J van 't Veer; Frits Sam van Dam; Kim Karsenberg; Kirsten Fl Douma; Harm van Tinteren; Johannes L Peterse; Jelle Wesseling; Tin S Wu; Douwe Atsma; Emiel Jt Rutgers; Guido Brink; Arno N Floore; Annuska M Glas; Rudi Mh Roumen; Frank E Bellot; Cees van Krimpen; Sjoerd Rodenhuis; Marc J van de Vijver; Sabine C Linn
Journal:  Lancet Oncol       Date:  2007-11-26       Impact factor: 41.316

10.  Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.

Authors:  Marc Buyse; Sherene Loi; Laura van't Veer; Giuseppe Viale; Mauro Delorenzi; Annuska M Glas; Mahasti Saghatchian d'Assignies; Jonas Bergh; Rosette Lidereau; Paul Ellis; Adrian Harris; Jan Bogaerts; Patrick Therasse; Arno Floore; Mohamed Amakrane; Fanny Piette; Emiel Rutgers; Christos Sotiriou; Fatima Cardoso; Martine J Piccart
Journal:  J Natl Cancer Inst       Date:  2006-09-06       Impact factor: 13.506

View more
  37 in total

1.  Disappearing breast cancers.

Authors:  S A Narod
Journal:  Curr Oncol       Date:  2012-04       Impact factor: 3.677

Review 2.  The benefits and harms of breast cancer screening: an independent review.

Authors:  M G Marmot; D G Altman; D A Cameron; J A Dewar; S G Thompson; M Wilcox
Journal:  Br J Cancer       Date:  2013-06-06       Impact factor: 7.640

3.  Earlier diagnosis of breast cancer outside of a screening programme.

Authors:  Chris I Flowers
Journal:  Nat Rev Clin Oncol       Date:  2013-07-23       Impact factor: 66.675

4.  Screening: biology dictates the fate of young women with breast cancer.

Authors:  Martin Eklund; Laura J Esserman
Journal:  Nat Rev Clin Oncol       Date:  2013-11-05       Impact factor: 66.675

5.  Breast cancer risk factor associations differ for pure versus invasive carcinoma with an in situ component in case-control and case-case analyses.

Authors:  Melanie Ruszczyk; Gary Zirpoli; Shicha Kumar; Elisa V Bandera; Dana H Bovbjerg; Lina Jandorf; Thaer Khoury; Helena Hwang; Gregory Ciupak; Karen Pawlish; Pepper Schedin; Patricia Masso-Welch; Christine B Ambrosone; Chi-Chen Hong
Journal:  Cancer Causes Control       Date:  2015-11-30       Impact factor: 2.506

6.  Addressing overdiagnosis and overtreatment in cancer: a prescription for change.

Authors:  Laura J Esserman; Ian M Thompson; Brian Reid; Peter Nelson; David F Ransohoff; H Gilbert Welch; Shelley Hwang; Donald A Berry; Kenneth W Kinzler; William C Black; Mina Bissell; Howard Parnes; Sudhir Srivastava
Journal:  Lancet Oncol       Date:  2014-05       Impact factor: 41.316

Review 7.  Breast cancer screening: the questions answered.

Authors:  Philippe Autier; Laura J Esserman; Chris I Flowers; Nehmat Houssami
Journal:  Nat Rev Clin Oncol       Date:  2012-08-14       Impact factor: 66.675

8.  Biological characteristics of interval cancers: a role for biomarkers in the breast cancer screening.

Authors:  A Caldarella; D Puliti; E Crocetti; S Bianchi; V Vezzosi; P Apicella; M Biancalani; A Giannini; C Urso; F Zolfanelli; E Paci
Journal:  J Cancer Res Clin Oncol       Date:  2012-09-09       Impact factor: 4.553

9.  Combining method of detection and 70-gene signature for enhanced prognostication of breast cancer.

Authors:  J M N Lopes Cardozo; M K Schmidt; L J van 't Veer; F Cardoso; C Poncet; E J T Rutgers; C A Drukker
Journal:  Breast Cancer Res Treat       Date:  2021-06-30       Impact factor: 4.872

10.  Complex Solid and Cystic Breast Cancer: A Series of Six Case Reports.

Authors:  Nishi Mehta; Lee Rousslang; Mohammad Shokouh-Amiri; Elizabeth L Wiley; Lauren Green
Journal:  J Radiol Case Rep       Date:  2020-02-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.